Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. - Wikidata - wikimedia - TriplyDB

Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics.

Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics.

http://www.wikidata.org/entity/Q42996149

about

Treatment of hepatitis C in children: a systematic review KASL clinical practice guidelines: management of hepatitis C Viral hepatitis B and C in children Diagnosis, management, and treatment of hepatitis C: an update Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016.Pegylated IFN-α and ribavirin: emerging data in the treatment of special populations.Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of Amer Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection.Ophthalmologic complications in children with chronic hepatitis C treated with pegylated interferon Hepatitis C in the pediatric population: transmission, natural history, treatment and liver transplantation.Treatment of hepatitis C virus infection Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Managing HCV infection in pediatric age group: suggested recommendations.The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C.Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children Treatment and follow up of children with chronic hepatitis C in Albania.Pegylated interferon for chronic hepatitis C in children affects growth and body composition: results from the pediatric study of hepatitis C (PEDS-C) trial.Perinatal hepatitis C virus infection: diagnosis and management Treatment options for chronic hepatitis B and C infection in children.Regional differences in hepatitis C treatment with peginterferon and ribavirin in Japan: a retrospective cohort study Management of chronic hepatitis C: consensus guidelines.Design of the PEDS-C trial: pegylated interferon +/- ribavirin for children with chronic hepatitis C viral infection.IL28B SNP rs12979860 is the Critical Predictor for Sustained Viral Response in Chinese Children Aged 1 to 6 Years with Chronic Hepatitis C.Safety and transparency of pediatric drug trials.Pediatric Dosing and Body Size in Biotherapeutics.Biotherapeutic bioanalysis: a multi-indication case study review.Chronic hepatitis C in children--review of natural history at a National Centre.Treatment of chronic viral hepatitis C in children and adolescents: UK experience.Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations.Systematic review with meta-analysis: comparison between therapeutic regimens for paediatric chronic hepatitis C.Efficacy and safety of pegylated interferon in children and adolescents infected with chronic hepatitis C: a preliminary study.Vertical genotype 1 HCV infection treated successfully in the second year of life: a case report.Association of Hepatitis C Virus Infection and Interleukin-28B Gene Polymorphism in Chinese Children.Interferon-α plus ribavirin yields 98 % sustained virologic response in children aged 1-5 years with iatrogenic chronic hepatitis C.Population pharmacokinetics of peginterferon alfa-2b in pediatric patients with chronic hepatitis C.Is liver biopsy mandatory in children with chronic hepatitis C?Spontaneous clearance of hepatitis C virus in vertically infected children.Long-term outcome of hepatitis C virus infections acquired after pediatric liver transplantation.Current treatment options and response rates in children with chronic hepatitis C.

P2860

Q21136318-4F877437-B657-4C63-B9F4-CE413F251C7B Q26752471-371EB520-674A-4AE2-AC86-723303560664 Q27473273-3948A7C9-A078-4859-8C5B-6F4E22C8AAB6 Q29619682-7852EAC8-4868-4B3A-BE2A-0DB0133BEDFB Q30355190-D15C3140-D5B3-4E56-A459-55317E781600 Q30733177-8C7F524D-A814-49F9-ADD4-36B12BDE7FCD Q33650105-DCE31BD7-8E82-448B-9604-A75680BC870D Q33827819-AC389836-45D8-4FFF-9768-B6A6CB89DE61 Q34023077-739D9D65-7891-4F23-B01A-C3618EB9468E Q34023159-F4F8B7CE-3FB7-4E60-946C-E14E3CE7A27B Q34093840-69871751-77F4-4C80-A6D1-3C2DE62C9AA4 Q34099424-53A23164-C9DF-4022-BAEF-C2748809DDF2 Q34212799-024C3E60-73D5-4771-B692-0AFD2140DEBA Q34411942-F3D3149E-AA60-40D0-A05E-0AE67E6DFBAF Q34588247-B2781BD1-937D-4248-85E2-F17AE7FB0BAD Q34861058-69909AEF-03CD-48BA-B7E2-A17B41E630A5 Q35735622-2624D88F-05D2-4248-B64A-1ADFBA8348F5 Q36055220-28F981D1-58F1-48D5-9B3F-7ACF623786F2 Q36153246-3275D536-49FC-49E0-9460-BF18D85C270F Q36607394-7CE56C6D-E1EE-4B0F-9CD1-20F36D355DCE Q36733568-1DFBE823-0192-4A19-BF66-8E1FFA9DE1EE Q36849347-1025574C-3821-4F9A-96D2-B73CD9B241AF Q37126749-C69F7672-4F8D-4ED2-81CB-485E653026A7 Q37428173-9D289B24-9285-494B-BC7A-FA5B68CC09D1 Q37472770-09B9578B-180F-480B-A62B-CF746577ACB6 Q37666711-DB34C0A1-7AF8-44BD-82BB-D7CD41CF634A Q37854629-7737F6BD-6DAD-422D-919E-D4C8E4EF6CC8 Q37931376-E0A991A5-EE49-4C20-8043-E9021CC09B0F Q38184887-05C07BF4-9A7C-4B20-ADC6-D3CF461D1897 Q38203823-95437393-5C41-4739-A4B7-267F2C9591D2 Q38450468-639EBAF6-8381-49C4-B50A-08CBA0D3BB04 Q38854176-4AC7DEDF-27E8-4352-91A0-883EB21BF9DF Q40265125-EB51D6D1-FE0E-4C2D-AB90-03F349F3202B Q40407622-BAB3B292-900F-4E50-9CA7-A8D6B17B7886 Q40961029-A8D0CAB7-331E-4444-A563-C6BF32DF4397 Q42615350-E6E72225-C2D9-41F3-9986-63FB49287B27 Q42909398-1F0288E5-7AAA-433F-AD08-A48A7AE0C99E Q43038366-79A6F46E-E116-43C4-8585-77A4BA866EF7 Q43040672-FADEB801-9431-4ADF-B6BC-3AC51DBA15B5 Q43046510-83965C00-E715-4C1C-A451-3CF821043AA8

P2860

Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics.

http://www.wikidata.org/entity/Q42996149

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Interferon alfa-2b in combinat ...... safety, and pharmacokinetics.

@en

Interferon alfa-2b in combinat ...... safety, and pharmacokinetics.

@nl

type

label

Interferon alfa-2b in combinat ...... safety, and pharmacokinetics.

@en

Interferon alfa-2b in combinat ...... safety, and pharmacokinetics.

@nl

prefLabel

Interferon alfa-2b in combinat ...... safety, and pharmacokinetics.

@en

Interferon alfa-2b in combinat ...... safety, and pharmacokinetics.

@nl

P1433

Q42996149-C03ADD81-5432-42F6-A0B1-16E78A8854B2

P1476

Q42996149-D730D1F3-BF45-4A2F-99FA-81B12D181B19

P2093

Q42996149-4047AA5C-157A-4E72-930C-2398C0DE1BE1

Q42996149-4388BF0F-13CD-4F54-B339-1B34B89AC7E2

Q42996149-74C3E231-B998-4A36-98A5-19B09BA1861C

Q42996149-81897316-CE47-4FE7-84C7-FD634FE1CB22

Q42996149-84DF7595-35E2-45F8-9DF8-4F3021321A63

Q42996149-9C4DC115-7873-4D9B-9E58-C010223DBC37

Q42996149-B48E439A-4C8A-45CA-8685-88FD9EBA8BBF

Q42996149-BA453694-A621-4F16-9573-766C5153B24D

Q42996149-D068BCD0-B3C9-46EC-8694-20447A10C73B

Q42996149-E445DCEC-9A37-4E10-B842-0B9B566C3751

P304

Q42996149-DA9B700D-DB5E-4084-B69D-4B3E40160A2E

P31

Q42996149-5E7BE855-0EA0-4C87-A1D3-5DFD1E43A5E9

P356

Q42996149-54A6A9B8-8265-42E7-83B0-3C005733225F

P407

Q42996149-9CD20031-6B2C-4A24-9D12-DB01EC04A1E5

P433

Q42996149-47462D5C-4781-4C2E-A0E5-A6F12F2D0C60

P478

Q42996149-68669B00-2EBD-42D0-993A-61806962BCFF

P50

Q42996149-632F7AA3-B1F3-49F6-9926-932A619FE0C8

P577

Q42996149-A31A3A15-EAA6-4BDA-A275-299E697B30D1

P5875

Q42996149-B3D0CE2C-4155-4411-8233-EB6F73D6515F

P698

Q42996149-4F4BFC7F-2DBD-4C88-9ECB-8B56E4BED7E4

P356

P1433

P1476

Interferon alfa-2b in combinat ...... safety, and pharmacokinetics.

@en

P2093

Andrew Baczkowski

http://www.w3.org/2001/XMLSchema#string

Barbara Haber

http://www.w3.org/2001/XMLSchema#string

Deirdre A Kelly

http://www.w3.org/2001/XMLSchema#string

Giorgina Mieli-Vergani

http://www.w3.org/2001/XMLSchema#string

International Pediatric Hepatitis C Therapy Group

http://www.w3.org/2001/XMLSchema#string

Karen F Murray

http://www.w3.org/2001/XMLSchema#string

Mark Laughlin

http://www.w3.org/2001/XMLSchema#string

Mark Shelton

http://www.w3.org/2001/XMLSchema#string

Maureen M Jonas

http://www.w3.org/2001/XMLSchema#string

Michael Geffner

http://www.w3.org/2001/XMLSchema#string

P304

1010-1018

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.20884

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P50

Jean P. Molleston

P577

2005-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7516668

http://www.w3.org/2001/XMLSchema#string

P698

16250032

http://www.w3.org/2001/XMLSchema#string